BioSpace News Archive

Alpha Tau Medical Ltd. (“Alpha Tau”, or the “Company”) (NASDAQ: DRTS, DRTSW), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT™, reported third quarter 2023 financial results and provided a corporate update.

Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the “Company” or “Marvel”), is pleased to announce a collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at iBrain Institute

Kiromic BioPharma, Inc. announces it has uplisted the trading of shares of its common stock from the OTC® Pink Market to the OTCQB® Venture Market, effective as of the opening of trading on Friday, November 17, 2023.

Bone Biologics Corporation announced that it has entered into a definitive agreement for the issuance and sale of an aggregate of 1,139,063 of its shares of common stock at a purchase price of $0.64 per share in a registered direct offering priced at-the-market under Nasdaq rules.

Fusion Pharmaceuticals Inc., and BWXT Medical Ltd., a subsidiary of BWX Technologies, Inc., announced that the companies have entered into a new agreement for the supply of generators to produce actinium-225, a medical isotope used to treat cancer in clinical trials.

LAVA Therapeutics N.V. announced recent corporate highlights and financial results for the quarter ended September 30, 2023.

ADMA Biologics, Inc. announced that it has received U.S. Food and Drug Administration approval for its tenth ADMA BioCenters plasma collection facility located in Laurel, Maryland.

Bioretec Ltd, a pioneer of biodegradable orthopedic implants, is initiating a new CEO recruitment process as the company’s current CEO, Mr. Timo Lehtonen, shall transfer into a new role within the company.

ROME Therapeutics, a biotechnology company harnessing the power of the dark genome to develop breakthrough medicines for serious diseases, announced new data validating the reverse transcriptase (RT) of LINE-1, an abundant repeat element in the dark genome, as a novel target for drug discovery in autoimmune diseases, including lupus.

BPGbio, Inc. today announced that researchers will present data from an ongoing phase 2 trial study of BPGbio lead candidate, BPM31510, in patients with newly diagnosed glioblastoma multiforme (GBM), at the Society for Neuro-Oncology Annual Meeting being held November 16-19, 2023 in Vancouver, Canada.